JP2016518438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518438A5 JP2016518438A5 JP2016513398A JP2016513398A JP2016518438A5 JP 2016518438 A5 JP2016518438 A5 JP 2016518438A5 JP 2016513398 A JP2016513398 A JP 2016513398A JP 2016513398 A JP2016513398 A JP 2016513398A JP 2016518438 A5 JP2016518438 A5 JP 2016518438A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- use according
- patient
- inhibitor
- glucosidase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 12
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 7
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 5
- 229960002397 linagliptin Drugs 0.000 claims description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 4
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 4
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 4
- 229960002632 acarbose Drugs 0.000 claims description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 229960001110 miglitol Drugs 0.000 claims description 4
- 229960001729 voglibose Drugs 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 201000006549 dyspepsia Diseases 0.000 claims description 3
- 206010016766 flatulence Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 230000002641 glycemic effect Effects 0.000 claims 3
- -1 4-methyl-quinazolin-2-yl Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 206010054805 Macroangiopathy Diseases 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 238000009094 second-line therapy Methods 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 238000009095 third-line therapy Methods 0.000 claims 1
- 238000004260 weight control Methods 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044858A JP7382147B2 (ja) | 2013-05-17 | 2019-03-12 | ＤＰＰ－４阻害薬とα－グルコシダーゼ阻害薬との組合せ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168375 | 2013-05-17 | ||
| EP13168375.7 | 2013-05-17 | ||
| PCT/EP2014/060160 WO2014184376A1 (en) | 2013-05-17 | 2014-05-16 | Combination of a dpp-4 inhibitor and an alpha-glucosidase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019044858A Division JP7382147B2 (ja) | 2013-05-17 | 2019-03-12 | ＤＰＰ－４阻害薬とα－グルコシダーゼ阻害薬との組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518438A JP2016518438A (ja) | 2016-06-23 |
| JP2016518438A5 true JP2016518438A5 (https=) | 2017-06-22 |
Family
ID=48430599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513398A Pending JP2016518438A (ja) | 2013-05-17 | 2014-05-16 | ＤＰＰ−４阻害薬とα−グルコシダーゼ阻害薬との組合せ |
| JP2019044858A Active JP7382147B2 (ja) | 2013-05-17 | 2019-03-12 | ＤＰＰ－４阻害薬とα－グルコシダーゼ阻害薬との組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019044858A Active JP7382147B2 (ja) | 2013-05-17 | 2019-03-12 | ＤＰＰ－４阻害薬とα－グルコシダーゼ阻害薬との組合せ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140343014A1 (https=) |
| EP (1) | EP2996724A1 (https=) |
| JP (2) | JP2016518438A (https=) |
| WO (1) | WO2014184376A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| US20240358055A1 (en) * | 2023-04-18 | 2024-10-31 | Richard Clark Kaufman | Dietary supplements for weight management and glycemic control |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000133A1 (es) * | 2007-01-19 | 2008-05-23 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e |
| JP5685550B2 (ja) * | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
-
2014
- 2014-05-16 WO PCT/EP2014/060160 patent/WO2014184376A1/en not_active Ceased
- 2014-05-16 EP EP14726923.7A patent/EP2996724A1/en not_active Withdrawn
- 2014-05-16 JP JP2016513398A patent/JP2016518438A/ja active Pending
- 2014-05-16 US US14/279,683 patent/US20140343014A1/en not_active Abandoned
-
2019
- 2019-03-12 JP JP2019044858A patent/JP7382147B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518438A5 (https=) | ||
| JP4643760B2 (ja) | Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| US20120040898A1 (en) | Pharmaceutical compositions | |
| CN103338760B (zh) | 保护血管及保护心脏的抗糖尿病性治疗 | |
| NZ625577A (en) | Therapeutic uses of pharmaceutical compositions | |
| NZ590787A (en) | DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy | |
| JP2015044875A5 (https=) | ||
| NZ605207A (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| CN109310697A (zh) | 利格列汀和二甲双胍的组合 | |
| JP2022529312A5 (https=) | ||
| JP2018509419A5 (https=) | ||
| JP2020536121A5 (https=) | ||
| US20240100127A1 (en) | Tirzepatide therapeutic methods | |
| Provilus et al. | Weight gain associated with antidiabetic medications | |
| Davis | Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus | |
| Davoren | Glucose-lowering medicines for type 2 diabetes | |
| CN116157132A (zh) | 一种降低血糖的组合、应用和方法 | |
| US9241956B2 (en) | Pharmaceutical preparation and method for treatment of diabetes | |
| US20060241136A1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| Pandit et al. | Obesity context of type 2 diabetes and medication perspectives | |
| Dollery | A clinician looks at the future | |
| Rosen et al. | Pharmacotherapy for obesity | |
| CN104027328A (zh) | 预防或治疗糖尿病的制剂 | |
| EP4393486A1 (en) | Compositions and methods for preventing or reducing the risk of metabolic syndrome | |
| AU2014221222B2 (en) | Pharmaceutical compositions |